Compare · CATB vs TRIL
CATB vs TRIL
Side-by-side comparison of Catabasis Pharmaceuticals, Inc. (CATB) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CATB and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL is the larger of the two at $1.94B, about 16.0x CATB ($121.4M).
- TRIL has more recent analyst coverage (5 ratings vs 2 for CATB).
- Company
- Catabasis Pharmaceuticals, Inc.
- Trillium Therapeutics Inc.
- Price
- $8.57-7.15%
- $19.30-3.45%
- Market cap
- $121.4M
- $1.94B
- 1M return
- -
- -3.79%
- 1Y return
- -
- -5.02%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 2
- 5
Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest CATB
- SEC Form SC 13D/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)
- SEC Form 4 filed by Violin Jonathan
- SEC Form SC 13G/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)
- Catabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
- Wedbush initiated coverage on Catabasis Pharmaceuticals with a new price target
- Catabasis Pharmaceuticals upgraded by HC Wainwright & Co. with a new price target
- Catabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-8 filed by Catabasis Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo